Skip to main content

Articles

Page 3 of 38

  1. Cancer cachexia is a deadly wasting syndrome that accompanies various diseases (including ~ 50% of cancers). Clinical studies have established that cachexia is not a nutritional deficiency and is linked to exp...

    Authors: Dong Wang, Xiaohui Li, Defeng Jiao, Ying Cai, Liting Qian, Yiqing Shen, Yichen Lu, Yonggang Zhou, Binqing Fu, Rui Sun, Zhigang Tian, Xiaohu Zheng and Haiming Wei
    Citation: Journal of Hematology & Oncology 2023 16:30
  2. Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induct...

    Authors: Rahul S. Bhansali, Keith W. Pratz and Catherine Lai
    Citation: Journal of Hematology & Oncology 2023 16:29
  3. The tumor microenvironment (TME) has been extensively investigated; however, it is complex and remains unclear, especially in elderly patients. Senescence is a cellular response to a variety of stress signals,...

    Authors: Binghao Zhao, Bo Wu, Nan Feng, Xiang Zhang, Xin Zhang, Yiping Wei and Wenxiong Zhang
    Citation: Journal of Hematology & Oncology 2023 16:28
  4. Acute myeloid leukemia (AML) is a deadly hematological malignancy. Cellular morphology detection of bone marrow smears based on the French–American–British (FAB) classification system remains an essential crit...

    Authors: Zebin Yu, Jianhu Li, Xiang Wen, Yingli Han, Penglei Jiang, Meng Zhu, Minmin Wang, Xiangli Gao, Dan Shen, Ting Zhang, Shuqi Zhao, Yijing Zhu, Jixiang Tong, Shuchong Yuan, HongHu Zhu, He Huang…
    Citation: Journal of Hematology & Oncology 2023 16:27
  5. Treatment options specifically for patients with locally advanced pancreatic adenocarcinoma (LAPC) are scare and chemotherapy alone delivers limited efficacy. Immunotherapy and radiotherapy are potential effec...

    Authors: Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen and Zhenwei Peng
    Citation: Journal of Hematology & Oncology 2023 16:26
  6. There are situations where non-first-degree (NFD) related donors have to be considered as alternatives to first-degree (FD) related donors for haploidentical hematopoietic cell transplantation (HAPLO). However...

    Authors: Yishan Ye, Myriam Labopin, Jia Chen, Zafer Gulbas, Xi Zhang, Yener Koc, Didier Blaise, Fabio Ciceri, Emmanuelle Polge, Mohamed Houhou, Lin Li, Yi Luo, Depei Wu, He Huang, Mohamad Mohty and Norbert-Claude Gorin
    Citation: Journal of Hematology & Oncology 2023 16:25
  7. The immunological composition of the tumor microenvironment has a decisive influence on the biological course of cancer and is therefore of profound clinical relevance. In this study, we analyzed the cooperati...

    Authors: Sandra Genduso, Vera Freytag, Daniela Schetler, Lennart Kirchner, Alina Schiecke, Hanna Maar, Daniel Wicklein, Florian Gebauer, Katharina Bröker, Christine Stürken, Karin Milde-Langosch, Leticia Oliveira-Ferrer, Franz L. Ricklefs, Florian Ewald, Gerrit Wolters-Eisfeld, Kristoffer Riecken…
    Citation: Journal of Hematology & Oncology 2023 16:23
  8. Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is accelerating. This analysis summarizes the data derived from the clinical trials conducted at MD Anderson between 1985 and 20...

    Authors: Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Mary Alma Welch, Farhad Ravandi and Hagop Kantarjian
    Citation: Journal of Hematology & Oncology 2023 16:22
  9. Despite mitochondrial DNA (mtDNA) mutations are common events in cancer, their global frequency and clinical impact have not been comprehensively characterized in patients with myelodysplastic neoplasia (also ...

    Authors: Jing Dong, Christopher Staffi Buradagunta, Tao Zhang, Stephen Spellman, Yung-Tsi Bolon, Amy E. DeZern, Shahinaz M. Gadalla, H. Joachim Deeg, Aziz Nazha, Corey Cutler, Chao Cheng, Raul Urrutia, Paul Auer and Wael Saber
    Citation: Journal of Hematology & Oncology 2023 16:21
  10. TP53 mutations, which are present in 5% to 10% of patients with acute myeloid leukemia (AML), are associated with treatment resistance and poor outcomes. First-line therapies for TP53-mutated (TP53m) AML consist ...

    Authors: Naval G. Daver, Shahed Iqbal, Camille Renard, Rebecca J. Chan, Ken Hasegawa, Hao Hu, Preston Tse, Jiajun Yan, Michael J. Zoratti, Feng Xie and Giridharan Ramsingh
    Citation: Journal of Hematology & Oncology 2023 16:19
  11. Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented...

    Authors: Katherine W. DiNardo, Thomas W. LeBlanc and Hui Chen
    Citation: Journal of Hematology & Oncology 2023 16:17
  12. The immunoglobulin J chain (Jchain) is highly expressed in the majority of multiple myeloma (MM), and Jchain-derived peptides presented in HLA molecules may be suitable antigens for T-cell therapy of MM.

    Authors: Miranda H. Meeuwsen, Anne K. Wouters, Tassilo L. A. Wachsmann, Renate S. Hagedoorn, Michel G. D. Kester, Dennis F. G. Remst, Dirk M. van der Steen, Arnoud H. de Ru, Els P. van Hees, Martijn Kremer, Marieke Griffioen, Peter A. van Veelen, J. H. Frederik Falkenburg and Mirjam H. M. Heemskerk
    Citation: Journal of Hematology & Oncology 2023 16:16
  13. The acute myeloid leukemia (AML) patients obtain limited benefits from current immune checkpoint blockades (ICBs), although immunotherapy have achieved encouraging success in numerous cancers. Here, we found t...

    Authors: Jianshan Mo, Lin Deng, Keren Peng, Shumin Ouyang, Wen Ding, Linlin Lou, Ziyou Lin, Jianzheng Zhu, Jingwei Li, Qiyi Zhang, Pengyan Wang, Yuanzhen Wen, Xiaobing Chen, Peibin Yue, Jin-Jian Lu, Kai Zhu…
    Citation: Journal of Hematology & Oncology 2023 16:15
  14. Authors: Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu, Bingcheng Liu, Yanli Zhang, Li Meng, Huanling Zhu, Xin Du, Suning Chen, Yang Liang, Yu Hu, Xiaoli Liu, Yongping Song, Lichuang Men…
    Citation: Journal of Hematology & Oncology 2023 16:13

    The original article was published in Journal of Hematology & Oncology 2022 15:113

  15. Authors: Chiara Fallerini, Sergio Daga, Elisa Benetti, Nicola Picchiotti, Kristina Zguro, Francesca Catapano, Virginia Baroni, Simone Lanini, Alessandro Bucalossi, Giuseppe Marotta, Francesca Colombo, Margherita Baldassarri, Francesca Fava, Giada Beligni, Laura Di Sarno, Diana Alaverdian…
    Citation: Journal of Hematology & Oncology 2023 16:11

    The original article was published in Journal of Hematology & Oncology 2021 14:123

  16. The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Hapl...

    Authors: Frédéric Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stölzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri and Mohamad Mohty
    Citation: Journal of Hematology & Oncology 2023 16:10
  17. Selectively targeting leukemia stem cells (LSCs) is a promising approach in treating acute myeloid leukemia (AML), for which identification of such therapeutic targets is critical. Increasing lines of evidence...

    Authors: Xiao-Na Zhu, Yu-Sheng Wei, Qian Yang, Hao-Ran Liu, Zhe Zhi, Di Zhu, Li Xia, Deng-Li Hong, Yun Yu and Guo-Qiang Chen
    Citation: Journal of Hematology & Oncology 2023 16:9
  18. RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or bacterial infection and induce host innate immune responses. The RLRs family comprises retinoic acid-inducible g...

    Authors: Yangfu Jiang, Hongying Zhang, Jiao Wang, Jinzhu Chen, Zeyu Guo, Yongliang Liu and Hui Hua
    Citation: Journal of Hematology & Oncology 2023 16:8
  19. The prognosis of pancreatic ductal adenocarcinoma (PDAC) is one of the most dismal of all cancers and the median survival of PDAC patients is only 6–8 months after diagnosis. While decades of research effort h...

    Authors: Yi Han, Pascal Drobisch, Alexander Krüger, Doreen William, Konrad Grützmann, Lukas Böthig, Heike Polster, Lena Seifert, Adrian M. Seifert, Marius Distler, Mathieu Pecqueux, Carina Riediger, Verena Plodeck, Heiner Nebelung, Georg F. Weber, Christian Pilarsky…
    Citation: Journal of Hematology & Oncology 2023 16:7
  20. Despite significant progress in clinical management, drug resistance remains a major obstacle. Recent research based on protein degradation to restrain drug resistance has attracted wide attention, and several...

    Authors: Hui Ming, Bowen Li, Jingwen Jiang, Siyuan Qin, Edouard C. Nice, Weifeng He, Tingyuan Lang and Canhua Huang
    Citation: Journal of Hematology & Oncology 2023 16:6
  21. T cell receptor (TCR)-T cells possess similar effector function, but milder and more durable signal activation compared with chimeric antigen receptor-T cells. TCR-T cell therapy is another active field of cel...

    Authors: Chenggong Li, Fen Zhou, Jing Wang, Qi Chang, Mengyi Du, Wenjing Luo, Yinqiang Zhang, Jia Xu, Lu Tang, Huiwen Jiang, Lin Liu, Haiming Kou, Cong Lu, Danying Liao, Jianghua Wu, Qiuzhe Wei…
    Citation: Journal of Hematology & Oncology 2023 16:5
  22. Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts and an increased risk of bleeding. Multiple humoral and cellular immune abnormalities re...

    Authors: Xin-guang Liu, Yu Hou and Ming Hou
    Citation: Journal of Hematology & Oncology 2023 16:4
  23. Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that currently combines the selectivity of monoclonal antibodies with the potency of a payload consisting of cytotoxic agents....

    Authors: Louise Conilh, Lenka Sadilkova, Warren Viricel and Charles Dumontet
    Citation: Journal of Hematology & Oncology 2023 16:3
  24. The antiphagocytic molecule CD47 is overexpressed in a wide variety of cancer cells, and antibodies targeting CD47 for cancer therapies are currently under intensive investigation. However, owing to the ubiqui...

    Authors: Yulu Li, Juan Liu, Wei Chen, Wei Wang, Fang Yang, Ximing Liu, Yao Sheng, Kaixin Du, Miaomiao He, Xueyuan Lyu, Huiyu Li, Linlin Zhao, Zhizhong Wei, Fengchao Wang, Sanduo Zheng and Jianhua Sui
    Citation: Journal of Hematology & Oncology 2023 16:2
  25. Hepatocellular carcinoma (HCC) generally arises from a background of liver cirrhosis (LC). Patients with cirrhosis and suspected HCC are recommended to undergo serum biomarker tests and imaging diagnostic eval...

    Authors: Tong Wu, Rong Fan, Jian Bai, Zhao Yang, Yun-Song Qian, Lu-Tao Du, Chun-Ying Wang, Ying-Chao Wang, Guo-Qing Jiang, Dan Zheng, Xiao-Tang Fan, Bo Zheng, Jing-Feng Liu, Guo-Hong Deng, Feng Shen, He-Ping Hu…
    Citation: Journal of Hematology & Oncology 2023 16:1
  26. Locally advanced non-small cell lung cancer (NSCLC) is frequent at diagnosis and requires multimodal treatment approaches. Neoadjuvant chemotherapy (NACT) followed by surgery is the treatment of choice for ope...

    Authors: Roberto Cuttano, Tommaso Colangelo, Juliana Guarize, Elisa Dama, Maria Pia Cocomazzi, Francesco Mazzarelli, Valentina Melocchi, Orazio Palumbo, Elena Marino, Elena Belloni, Francesca Montani, Manuela Vecchi, Massimo Barberis, Paolo Graziano, Andrea Pasquier, Julian Sanz-Ortega…
    Citation: Journal of Hematology & Oncology 2022 15:178
  27. Anti-CD38 monoclonal antibodies (mAbs), daratumumab, and isatuximab have represented a breakthrough in the treatment of multiple myeloma (MM). Recently, CD38-based mAbs were expected to achieve increasing pote...

    Authors: Guangbing Zhang, Cuiyu Guo, Yan Wang, Xianda Zhang, Shuang Liu, Wen Qu, Chunxia Chen, Lingli Yan, Zhouning Yang, Zhixiong Zhang, Xiaohua Jiang, Xiaofeng Chen, Hong Liu, Qinhuai Lai, Xian Wei, Ying Lu…
    Citation: Journal of Hematology & Oncology 2022 15:177
  28. tRNA-derived fragments (tRFs) are a class of small RNAs that occur when tRNAs are broken down by enzymes due to stress. Increasing reports have shown that tRFs are associated with multiple physiological and pa...

    Authors: Sicheng Lu, Xiaoman Wei, Lihuiping Tao, Dan Dong, Wenlong Hu, Qinchang Zhang, Yuquan Tao, Chengtao Yu, Dongdong Sun and Haibo Cheng
    Citation: Journal of Hematology & Oncology 2022 15:176
  29. Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) ba...

    Authors: Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O’Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park…
    Citation: Journal of Hematology & Oncology 2022 15:170
  30. Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biologica...

    Authors: Xuhui Tong, Rong Tang, Mingming Xiao, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Xianjun Yu and Si Shi
    Citation: Journal of Hematology & Oncology 2022 15:174
  31. Immunotherapy has transformed cancer treatments; however, a large fraction of patients encounter resistance. Such resistance is mediated by complex factors, often involving interactions between multiple genes....

    Authors: Jonathan J. Park, Adan Codina, Lupeng Ye, Stanley Lam, Jianjian Guo, Paul Clark, Xiaoyu Zhou, Lei Peng and Sidi Chen
    Citation: Journal of Hematology & Oncology 2022 15:172
  32. Acute myeloid leukemia (AML) is a fatal clonal hematopoietic malignancy, which results from the accumulation of several genetic aberrations in myeloid progenitor cells, with a worldwide 5-year survival prognos...

    Authors: Nicole Bäumer, Annika Scheller, Lisa Wittmann, Andreas Faust, Mara Apel, Subbaiah Chary Nimmagadda, Christiane Geyer, Katharina Grunert, Neele Kellmann, Matthias Peipp, Sareetha Kailayangiri, Matias Ezequiel Gutierrez Suburu, Cristian A. Strassert, Mathias Schenk, Lilo Greune, Christian Rüter…
    Citation: Journal of Hematology & Oncology 2022 15:171
  33. Since the emergence of the Omicron variant of SARS-CoV-2, though considered less virulent, hospitalization and death rates among immunocompromised patients remain high, especially for poor responders to vaccin...

    Authors: Ludovic Jondreville, Maud D’Aveni, Hélène Labussière-Wallet, Amandine Le Bourgeois, Alban Villate, Ana Berceanu, Silvia-Maria Bezsera, Anne Thiebaut, Marion Boissard-Simonet, Marlène Legrand, Jérôme Cornillon, Marie-Thérèse Rubio, Patrice Chevallier and Stéphanie Nguyen
    Citation: Journal of Hematology & Oncology 2022 15:169
  34. Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with poor prognosis. Proteogenomic characterization and integrative proteomic analysis provide a functional context to annotate genomic abnormal...

    Authors: Yexin Tong, Mingjun Sun, Lingli Chen, Yunzhi Wang, Yan Li, Lingling Li, Xuan Zhang, Yumeng Cai, Jingbo Qie, Yanrui Pang, Ziyan Xu, Jiangyan Zhao, Xiaolei Zhang, Yang Liu, Sha Tian, Zhaoyu Qin…
    Citation: Journal of Hematology & Oncology 2022 15:168
  35. A novel recombinant SIRPα-Fc fusion protein, IMM01, was constructed and produced using an in-house developed CHO-K1 cell expression system, and the anti-tumor mechanism of IMM01 targeting the CD47-SIRPα pathwa...

    Authors: Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang…
    Citation: Journal of Hematology & Oncology 2022 15:167
  36. Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL). The first-in-class covalent BTK inhibitor,...

    Authors: Elizabeth M. Muhowski, Janani Ravikrishnan, Britten Gordon, Lianbo Yu, Shrilekha Misra, Brandi Walker, Sudharshan Eathiraj, Deepa Sampath, Kerry A. Rogers, John C. Byrd and Jennifer A. Woyach
    Citation: Journal of Hematology & Oncology 2022 15:166
  37. The prognosis for metastatic and recurrent tumors of the central nervous system (CNS) remains dismal, and the need for newer therapeutic targets and modalities is critical. The cell surface glycoprotein B7H3 i...

    Authors: Kim Kramer, Neeta Pandit-Taskar, Brian H. Kushner, Pat Zanzonico, John L. Humm, Ursula Tomlinson, Maria Donzelli, Suzanne L. Wolden, Sophia Haque, Ira Dunkel, Mark M. Souweidane, Jeffrey P. Greenfield, Satish Tickoo, Jason S. Lewis, Serge K. Lyashchenko, Jorge A. Carrasquillo…
    Citation: Journal of Hematology & Oncology 2022 15:165
  38. Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct recognition of surface ligands, without prior sensitization. Allogeneic NK transfer is a highly valuable treatment opti...

    Authors: Nina Lamers-Kok, Denise Panella, Anna-Maria Georgoudaki, Haiping Liu, Didem Özkazanc, Lucia Kučerová, Adil Doganay Duru, Jan Spanholtz and Monica Raimo
    Citation: Journal of Hematology & Oncology 2022 15:164
  39. Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes in patients with relapsed/refractory disease, despite the improvements in intensive standard therapy. The leukaemic cells of paediatri...

    Authors: Simona Caruso, Biagio De Angelis, Francesca Del Bufalo, Roselia Ciccone, Samantha Donsante, Gabriele Volpe, Simona Manni, Marika Guercio, Michele Pezzella, Laura Iaffaldano, Domenico Alessandro Silvestris, Matilde Sinibaldi, Stefano Di Cecca, Angela Pitisci, Enrico Velardi, Pietro Merli…
    Citation: Journal of Hematology & Oncology 2022 15:163
  40. No fully validated risk-stratification strategies have been established in China where colonoscopies resources are limited. We aimed to develop and validate a fecal immunochemical test (FIT)-based risk-stratif...

    Authors: Shengbing Zhao, Shuling Wang, Peng Pan, Tian Xia, Rundong Wang, Quancai Cai, Xin Chang, Fan Yang, Lun Gu, Zixuan He, Jiayi Wu, Qianqian Meng, Tongchang Wang, Qiwen Fang, Xiaomei Mou, Honggang Yu…
    Citation: Journal of Hematology & Oncology 2022 15:162
  41. Hepatocarcinogenesis is driven by necroinflammation or metabolic disorders, and the underlying mechanisms remain largely elusive. We previously found that retinoic acid-inducible gene-I (RIG-I), a sensor for r...

    Authors: Zhenyang Li, Ye Zhou, Kaiwei Jia, Yingyun Yang, Liyuan Zhang, Suyuan Wang, Yue Dong, Mu Wang, Yunhui Li, Shan Lu, Wannian Zhang, Luxin Zhang, Yiwen Fan, Dingji Zhang, Nan Li, Yizhi Yu…
    Citation: Journal of Hematology & Oncology 2022 15:161
  42. Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death worldwide. Countless CRC patients undergo disease progression. As a hallmark of cancer, Warburg effe...

    Authors: Xinyang Zhong, Xuefeng He, Yaxian Wang, Zijuan Hu, Huixia Huang, Senlin Zhao, Ping Wei and Dawei Li
    Citation: Journal of Hematology & Oncology 2022 15:160

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2022 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    74 days submission to accept (Median)

    2022 Usage 
    2,836,875 downloads
    9,883 Altmetric mentions 

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here